GESLabs

What GESLabs does

GESLabs is a London-based, privately held biotech company founded in 2018 that develops therapeutic actives derived from cannabinoids for medical cannabis applications. The company positions itself at the ingredient/api layer of the medical cannabis value chain, producing cannabinoid-derived therapeutic compounds rather than formulated consumer or patient-facing drug products. As of available data, GESLabs operates with 11-50 employees under founder Peter Nel, suggesting an early-to-growth stage specialty biotech. The underlying technical platform — including extraction methods, purification processes, target therapeutic indications, and any proprietary strain or synthesis IP — is not disclosed in the available source material, nor are patents, certifications, or GMP status confirmed. No product catalog, pricing, distribution channel, or customer information has been published in the sources reviewed.

The company's business model cannot be characterized with precision from available evidence: no pricing model, revenue mechanics, customer segments, or go-to-market motion is documented. Implicitly, a cannabinoid-actives developer at this scale and stage would typically generate revenue via B2B API/ingredient supply to formulators, contract manufacturing, or licensing — but none of these are confirmed for GESLabs. The company has no disclosed funding rounds, no disclosed partnerships or alliances, and no disclosed regulatory milestones (e.g., clinical trials, MHRA licensing, Novel Food authorization) in the source data. The website at geslabs.com, when scraped, returned only a loader/verification placeholder with no substantive company content, which is itself a negative diligence signal given the absence of investor-grade disclosures.

Name

GESLabs

Website

https://geslabs.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

GESLabs is a London-based biotech company founded in 2018 that develops therapeutic actives derived from cannabinoids for medical cannabis applications, operating privately with 11-50 employees under founder Peter Nel.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

GESLabs is a biotech company that develops and supplies therapeutic actives derived from cannabinoids in medical cannabis. The company produces active ingredients from cannabis biomass intended for downstream therapeutic and pharmaceutical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutic Actives from Cannabinoids

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Avicanna: Canadian biopharmaceutical company commercializing cannabinoid-based pharmaceutical and dermo-cosmetic products. Comparable as a smaller, research-driven player building cannabinoid actives and formulations for medical use.
• Demetrix: Biotech (acquired by Cronos Group) that produced rare cannabinoids via fermentation for pharmaceutical and consumer applications. Comparable as a biotech-led developer of high-purity cannabinoid actives, differentiated by biosynthesis route.
• InMed Pharmaceuticals: Clinical-stage biotech developing cannabinoid-based therapies, including proprietary manufacturing approaches for rare cannabinoids. Directly comparable as a smaller, science-driven cannabinoid therapeutics specialist.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals in 2021, the originator of Sativex and Epidiolex — the benchmark cannabinoid-derived therapeutic products globally. Most directly comparable peer to GESLabs' cannabinoid-therapeutic actives model, though at vastly larger scale and with approved drugs on the market.
• Oxford Cannabinoid Technologies: UK-listed cannabinoid pharmaceutical company developing prescription cannabinoid-based therapeutics. Direct comparable on geography (UK) and on the model of turning cannabinoid actives into regulated, clinically validated therapeutics.
• Celadon Pharmaceuticals: UK-based medical cannabis company focused on producing GMP-grade cannabinoid APIs for clinical and commercial use. Highly comparable UK peer targeting the same therapeutic-actives layer that GESLabs operates in.

Broad incumbents

• Canopy Growth: Major global cannabis operator with medical, wellness, and pharmaceutical-facing lines, including cannabinoid-derived product development. Comparable as a broad incumbent that overlaps with GESLabs at the medical/therapeutic cannabis layer.
• Aurora Cannabis: Large Canadian medical and consumer cannabis company with EU GMP-certified production supplying European medical cannabis markets. Overlaps with GESLabs in supplying medically regulated cannabinoid material into European channels.
• Cronos Group: Global cannabis company that owns Demetrix and has cannabinoid bioprocessing and therapeutics exposure. Relevant incumbent with both consumer cannabis and biotech-style cannabinoid active ingredient operations.
• Tilray Brands: Large global cannabis company with a meaningful medical cannabis and pharmaceutical division. Relevant incumbent that competes across the medical-cannabis value chain, including cannabinoid-based therapeutic products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/geslabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GESLabs